drugset / Trial / NCT04988308
A Study of Bermekimab for the Treatment of Participants With Moderate to Severe Hidradenitis Suppurativa
RandomizedParallel-groupDouble-blindTreatment
Summary
The purpose of this study is to evaluate the clinical efficacy of bermekimab in participants with moderate to severe Hidradenitis Suppurativa (HS).
Timeline
- Start
- 2021-10-12
- Primary completion
- 2022-10-14
- Completion
- 2022-11-23
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Adalimumab | Monoclonal antibody | 40 mg | Subcutaneous |
| Subject | Bermekimab | Monoclonal antibody | — | Subcutaneous |